<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Schizophr Bull</journal-id><journal-id journal-id-type="iso-abbrev">Schizophr Bull</journal-id><journal-id journal-id-type="publisher-id">schbul</journal-id><journal-title-group><journal-title>Schizophrenia Bulletin</journal-title></journal-title-group><issn pub-type="ppub">0586-7614</issn><issn pub-type="epub">1745-1701</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5887970</article-id><article-id pub-id-type="doi">10.1093/schbul/sby014.065</article-id><article-id pub-id-type="publisher-id">sby014.065</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Concurrent Symposia</subject></subj-group></subj-group></article-categories><title-group><article-title>17.1 A RANDOMIZED CONTROLLED TRIAL OF CANNABIDIOL IN SCHIZOPHRENIA</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>McGuire</surname><given-names>Philip</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Robson</surname><given-names>Philip</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Cuba&#x00142;a</surname><given-names>Wies&#x00142;aw</given-names></name><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Vasile</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Morrison</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Barron</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Wright</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Institute of Psychiatry, Psychology &#x00026; Neuroscience, King&#x02019;s College London</aff><aff id="AF0002"><label>2</label>GW Pharmaceuticals</aff><aff id="AF0003"><label>3</label>Medical University of Gda&#x00144;sk</aff><aff id="AF0004"><label>4</label>Central Military Emergency University Hospital, Bucharest</aff><pub-date pub-type="ppub"><month>4</month><year>2018</year></pub-date><pub-date iso-8601-date="2018-04-01" pub-type="epub"><day>01</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>4</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>44</volume><issue>Suppl 1</issue><issue-title>Abstracts for the Sixth Biennial SIRS Conference</issue-title><fpage>S27</fpage><lpage>S27</lpage><permissions><copyright-statement>&#x000a9; Maryland Psychiatric Research Center 2018.</copyright-statement><copyright-year>2018</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="sby014.065.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Both preclinical and human research suggest that cannabidiol (CBD) has antipsychotic properties. This study assessed the safety and effectiveness of CBD in patients with schizophrenia.</p></sec><sec id="s2"><title>Methods</title><p>Patients with schizophrenia (n=88) were randomized to receive CBD (1000 mg/day) or placebo alongside their existing antipsychotic medication for 6 weeks. Participants were assessed before and after treatment using the PANSS, BACS, GAF scales, and the CGI Improvement and Severity scales.</p></sec><sec id="s3"><title>Results</title><p>Compared those given placebo, patients treated with CBD had lower levels of positive psychotic symptoms (PANSS; p=0.02), and were more likely to have been rated by clinicians as improved (CGI-I; p=0.02) and as not severely unwell (CGI-S; p=0.04). Patients who received CBD also showed trends for greater improvements in cognitive performance (BACS; p=0.07) and in overall functioning (GAF; p=0.08). There was no difference in the frequency of CBD of adverse events between CBD and placebo.</p></sec><sec id="s4"><title>Discussion</title><p>These data suggest that CBD has beneficial effects in patients with schizophrenia and is not associated with significant adverse effects.</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>